Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EBIT (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBIT for 2 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 9.65% to -$4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.6 million, a N/A change, with the full-year FY2025 number at -$1.1 million, up 71.01% from a year prior.
  • EBIT was -$4.1 million for Q4 2025 at Neuphoria Therapeutics, up from -$5.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $12.0 million in Q1 2025 to a low of -$5.8 million in Q2 2025.